Detection of Gas6/AXL complex and its expression changes in patients with ST-segment elevation myocardial infarction
Zhao Yin1,2,3, Xiaohua Nie4, Tianlun Li1,2
1Postgraduate School, Medical School of Chinese PLA, Beijing, China.
Frontiers in Medicine
|September 11, 2025
Summary
Researchers developed a novel antibody to detect the Gas6/AXL complex, finding it elevated in acute myocardial infarction patients. This Gas6/AXL complex shows promise as a sensitive biomarker for ST-segment elevation myocardial infarction.
Area of Science:
- Biochemistry
- Immunology
- Cardiovascular Research
Background:
- The Gas6/AXL signaling pathway is implicated in various diseases.
- A lack of specific antibodies has hindered understanding of the Gas6/AXL complex in disease.
- Circulating Gas6/AXL complex levels and their clinical significance remain largely uncharacterized.
Purpose of the Study:
- To develop a specific monoclonal antibody targeting the Gas6/AXL complex.
- To investigate the utility of this antibody in detecting the Gas6/AXL complex in human blood.
- To evaluate the Gas6/AXL complex as a potential biomarker in acute myocardial infarction (AMI).
Main Methods:
- Monoclonal antibodies (mAbs) against human AXL protein were generated in mice.
- Flow cytometry was employed for antibody screening and binding region mapping.
- An ELISA assay was developed using a novel AXL-Gas6 specific mAb to quantify the complex in human blood.
Main Results:
- A unique AXL monoclonal antibody specifically binding to the Gas6/AXL complex was successfully developed.
- The antibody confirmed AXL binding to Gas6 on human peripheral dendritic cells (pDCs).
- The Gas6/AXL complex was found to be significantly elevated in patients with AMI.
- The measured Gas6/AXL complex demonstrated higher sensitivity and risk factor prediction for ST-segment elevation myocardial infarction compared to commercial AXL kits.
Conclusions:
- A novel, specific antibody for the Gas6/AXL complex has been developed.
- The Gas6/AXL complex is a significantly elevated and sensitive biomarker in AMI patients.
- This complex holds potential as a valuable diagnostic and prognostic tool for ST-segment elevation myocardial infarction.
More Related Videos
04:41Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
8.6K
06:38Simultaneous 3D Analysis of Cardiac Damage and Immune Response in Reperfused Acute Myocardial Infarction Using Light Sheet Fluorescence Microscopy
Published on: September 26, 2025
1.1K
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
219
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
219
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
805
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
805
01:22Aortic Regurgitation II: Clinical Features and Diagnostic Tests
420
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
420
01:30Acute Coronary Syndrome I: Introduction
835
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
835
01:27Myocarditis II: Clinical Features and Diagnostic Tests
269
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
269